Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.42 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL796806 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL285025 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL8476888 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL3484269 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL8008057 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL11262527 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL9463339 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL1555719 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL16010887 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL7355491 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-117580836-A | Pyrimidine ring structure derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117062813-A | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116888100-A | High-activity HPK1 kinase inhibitor | 杭州阿诺生物医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022199662-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | 四川汇宇制药股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10780074-B2 | Compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3661929-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111183138-A | Isochroman compounds and uses | 赛诺维信制药公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2019-02-07 | — | — | US | disclosed |
| EP-0626068-A1 | LUMINESCENT LANTHANIDE CHELATES | WALLAC OY (FI) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | CHRM5 395/4885CHRM1 904/4885CHRM3 831/4885 |
| US-10780074-B2 | Compounds and uses thereof | PYGB, NLN, MAOB | CHRM5 395/4885CHRM1 904/4885CHRM3 831/4885 |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | CHRM5 395/4885CHRM1 904/4885CHRM3 831/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | CHRM5 2432/4885CHRM1 888/4885CHRM3 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.